There is a version of this story that starts with a breakthrough, a device, a patent, a pivotal clinical trial, but Chris Kiple would tell it differently.
“There was nothing more energizing than listening to patients’ challenges and working with our team to develop real-world solutions to improve lives,” Kiple says. For him, invention was never the point. Getting it to the people who needed it, that was the job.
That distinction might seem small. In medtech, it is everything. The gap between a promising technology and one that actually reaches patients is wide, and the wreckage on either side of it is significant. Companies with genuinely useful innovations stall at regulatory submission, collapse under reimbursement complexity, or simply run out of runway before a commercial team can carry the product forward. The science was sound. The system broke down.
Kiple has spent the better part of the last decade navigating that system, first at Ventec Life Systems, and now as CEO of Solius Labs and chair of the board at Lungpacer Medical. His perspective is less that of an inventor and more that of someone who has learned, often the hard way, what it takes for a healthcare technology to survive contact with the real world.
The Real Work Starts After the Idea
Every medtech product that reaches a patient has cleared an obstacle course most people never see. There is R&D, yes, but behind that is a regulatory strategy that has to be built early, not bolted on after the device is already designed. There is a reimbursement pathway that determines whether a hospital can afford to adopt the technology at all. There is manufacturing that has to scale without compromising quality. And there is a clinical layer, physicians, nurses, and allied health professionals, who have to trust the product enough to use it.
None of that happens automatically. And none of it happens without people.
Christopher Kiple’s time at Ventec illustrated this as clearly as anything could. VOCSN, the multi-function ventilator developed there, combined six separate medical devices into a single portable system, an engineering achievement that earned recognition from GeekWire, Medtech Breakthrough, and Red Dot. But the product did not move on recognition alone. It moved because teams across every function, from clinical affairs to supply chain, were doing their work in coordination with one another, aligned around a shared objective.
Kiple did not build it. A lot of people did. His role, by his own account, was to bring them together and get out of their way. That sounds modest. In practice, it is one of the harder things to do well in an industry where technical ambition often outpaces organizational discipline. Knowing when to lead and when to step back is itself a skill, and not a common one.
When the Mission Gets Complicated
Nothing tests a team like a crisis. In 2020, as COVID-19 was overwhelming hospitals and exhausting the global supply of critical care ventilators, Ventec entered an unlikely partnership with General Motors. The goal was to scale ventilator production by 80 times in under six months.
That is not a number that gets achieved by optimizing a process. It requires reinventing one.
The partnership was later recognized by Fast Company as one of the top 10 most innovative joint ventures of 2021 and by the Project Management Institute as one of the most influential projects of 2020. But the more lasting outcome, at least from Kiple’s vantage point, was the lesson embedded in the collaboration itself.
“I learned an incredible amount from the GM team,” Kiple says, “and was inspired by how people can come together to do the impossible.”
In an industry where executives often lead with outcomes, Kiple keeps returning to process, the mechanics of collaboration, the discipline of listening, the organizational humility required to absorb skills from people outside your field. The auto industry knows things the medtech industry doesn’t. The medtech industry returns the favor. And the patients, ultimately, are the ones who benefit from that exchange.
The GM partnership also forced a kind of organizational reckoning that most companies never face under ordinary conditions. Supply chains had to be rebuilt. Quality systems had to be adapted. Engineering assumptions that seemed fixed turned out to be flexible when the stakes were high enough and the right people were in the room. That experience left a mark on the company, on the people who lived it, and on Kiple’s own understanding of what teams are capable of when obstacles are removed and the mission is clear.
Christopher Kiple on What Teams Actually Need
The question of leadership in medtech tends to get answered with strategy decks and org charts. Chris Kiple’s answer is more straightforward. Talented people need to be found, supported, and trusted.
That sounds simple. It isn’t.
In high-stakes healthcare environments, the pressure to control outcomes can push leadership toward micromanagement, especially when regulatory timelines are tight and investors are watching. The instinct is understandable. The result is usually slower, not faster. It creates friction where there should be momentum, and it signals to capable people that their judgment is not trusted, which is precisely the kind of signal that drives them elsewhere.
What Chris Kiple describes instead is a leadership posture built around removing obstacles and creating the conditions for good work. This is not passive management. It requires active attention to where a team is stuck, what resources are missing, and which decisions need to be made at the top so that everything can keep moving.
There is also something to be said for the diversity of background that Kiple brings to these conversations. His career moved through finance at J.P. Morgan, law at Sidley Austin, and government affairs at Husch Blackwell before landing in medtech. That is an unusual path. And while none of those fields are obvious preparation for running a medical device company, each one contributed something, an understanding of capital markets, a discipline around regulatory language, an awareness of how policy shapes the environment in which healthcare products live or die. Cross-functional leadership is easier when the person at the top has actually worked across functions.
At Lungpacer Medical, where technology is being developed to help wean critically ill patients off mechanical ventilators and out of the ICU faster, the stakes of getting this right are not abstract. These are not lifestyle products. They are interventions for people in serious medical need, often at the most vulnerable moments of their lives. The margin for organizational dysfunction is essentially zero. Getting the team right, the systems right, and the product to the patient, in that order, with each stage genuinely supporting the next, is the only version of success that counts.
Patients as the Organizing Principle
The medtech industry talks a great deal about patient-centricity. It is, by now, a familiar phrase, earnest in intention, sometimes hollow in practice. What distinguishes organizations that actually operate this way is not the language they use but the decisions they make when trade-offs are hard.
Christopher Kiple has been consistent on this point across different companies and different product categories. Patient input is not a checkbox at the end of the development process. It belongs at the beginning, informing what gets built, and throughout every subsequent stage, shaping how the product gets refined in response to real-world use. The most technically elegant device in the world fails if patients cannot use it, afford it, or access a physician who will prescribe it.
This is also, practically speaking, a commercial argument. Products designed with genuine patient input tend to perform better in clinical adoption. They generate the kind of outcomes data that supports reimbursement conversations with payers. They tend to be the ones that earn the trust of healthcare professionals and, through that trust, actually get used. Patient engagement is not charity. It is infrastructure.
At Solius Labs, where Kiple now leads efforts to develop novel medical light therapy solutions, that same orientation applies. The specific therapeutic area is different. The underlying logic is not. Understand the patient experience first. Build toward it. Let that understanding drive every decision downstream, from how the device is designed to how it is packaged, priced, and supported after the sale.
There is a throughline in all of this that is easy to miss if you are focused on any one company or any one product. The throughline is that healthcare innovation is not a solo endeavor, and it never has been.
The broader lesson from Kiple’s work across Solius Labs, Ventec, and Lungpacer is not really about any one of those companies. It is about a model of healthcare innovation that takes the full journey seriously, from first prototype to patient bedside, and everything in between. That journey is collective. It always has been. The teams that understand this, and build their organizations accordingly, tend to be the ones that finish it.
